| abstract |
Modified natriuretic compounds and conjugates thereof are described herein. In particular, the conjugated form of hBNP is provided to include at least one modification moiety attached thereto. The modified natriuretic compound conjugates have activity in stimulating cGMP products, bind to NPR-A receptors, and in some embodiments have improved half-life in circulation compared to unmodified counterpart natriuretic compounds. Oral, parenteral, intestinal, subcutaneous, pulmonary, and venous forms of the compounds and conjugates may also be prepared as treatments and / or theraphies for heart disease, particularly congestive heart failure. Modified moieties including oligomeric structures having various lengths and shapes are also described. Analogs of natriuretic compounds are also described as having amino acid sequences other than the natural sequence.n n n n Natriuretic, conjugates, moieties |